Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites

Blood

Volumn 125, Issue 3, 2015, Pages 534-541

  Smith, Clare M ^a,b,l   Jerkovic, Ante ^c   Puy, Hervé ^d,e,f   Winship, Ingrid ^g,h   Deybach, Jean Charles ^d,e   Gouya, Laurent ^e,f   Van Dooren, Giel ⁱ   Goodman, Christopher Dean ^g   Sturm, Angelika ^g   Manceau, Hana ^d,e   McFadden, Geoffrey Ian ^g   David, Peter ^j   Mercereau Puijalon, Odile ^j   Burgio, Gaétan ^c   McMorran, Brendan J ^c   Foote, Simon J ^c,k  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^f Laboratory of Excellence GR Ex   (France)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^j CNRS   (France)

^k Australian National University   (Australia)

^l UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FERROCHELATASE; N METHYLPROTOPORPHYRIN; HEME; N-METHYLPROTOPORPHYRIN IX; PROTOPORPHYRIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHROCYTE; ERYTHROPOIETIC PROTOPORPHYRIA; FEMALE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GROWTH CURVE; HOST; HUMAN; HUMAN CELL; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PARASITE GROWTH; PARASITE PHENOMENA AND FUNCTIONS; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM CHABAUDI; PLASMODIUM CHABAUDI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SCHIZONT; SURVIVAL; TROPHOZOITE; X CHROMOSOME DOMINANT DISORDER; X LINKED DOMINANT PROTOPORPHYRIA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; MALARIA, FALCIPARUM; METABOLISM; PARASITOLOGY; PHENOTYPE; PHYSIOLOGY; PROTOPORPHYRIA, ERYTHROPOIETIC;

ANIMALS; ERYTHROCYTES; FEMALE; FERROCHELATASE; HEME; HUMANS; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; PLASMODIUM BERGHEI; PROTOPORPHYRIA, ERYTHROPOIETIC; PROTOPORPHYRINS;

EID: 84922145857     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-567149     Document Type: Article

References (41)

1. Hill AV. The immunogenetics of resistance to malaria. Proc Assoc Am Physicians. 1999;111(4):272-277.
2. Min-Oo G, Gros P. Erythrocyte variants and the nature of their malaria protective effect. Cell Microbiol. 2005;7(6):753-763.
3. Nagel RL, Roth EF Jr. Malaria and red cell genetic defects. Blood. 1989;74(4):1213-1221.
4. Bonday ZQ, Dhanasekaran S, Rangarajan PN, Padmanaban G. Import of host deltaaminolevulinate dehydratase into the malarial parasite: identification of a new drug target. Nat Med. 2000;6(8):898-903.
5. Dhanasekaran S, Chandra NR, Chandrasekhar Sagar BK, Rangarajan PN, Padmanaban G. Delta-aminolevulinic acid dehydratase from Plasmodium falciparum: indigenous versus imported. J Biol Chem. 2004;279(8):6934-6942.
6. Koncarevic S, Rohrbach P, Deponte M, et al. The malarial parasite Plasmodium falciparum imports the human protein peroxiredoxin 2 for peroxide detoxification. Proc Natl Acad Sci USA. 2009;106(32):13323-13328.
7. Sicard A, Semblat JP, Doerig C, et al. Activation of a PAK-MEK signalling pathway in malaria parasite-infected erythrocytes. Cell Microbiol. 2011;13(6):836-845.
8. Varadharajan S, Sagar BK, Rangarajan PN, Padmanaban G. Localization of ferrochelatase in Plasmodium falciparum. Biochem J. 2004;384(Pt 2):429-436.
9. Padmanaban G, Rangarajan PN. Heme metabolism of Plasmodium is a major antimalarial target. Biochem Biophys Res Commun. 2000;268(3):665-668.
10. Nagaraj VA, Sundaram B, Varadarajan NM, et al. Malaria parasite-synthesized heme is essential in the mosquito and liver stages and complements host heme in the blood stages of infection. PLoS Pathog. 2013;9(8):e1003522.
11. van Dooren GG, Kennedy AT, McFadden GI. The use and abuse of heme in apicomplexan parasites. Antioxid Redox Signal. 2012;17(4):634-656.
12. Pasini EM, Kirkegaard M, Mortensen P, Lutz HU, Thomas AW, Mann M. In-depth analysis of the membrane and cytosolic proteome of red blood cells. Blood. 2006;108(3):791-801.
13. Pasini EM, Kirkegaard M, Mortensen P, Mann M, Thomas AW. Deep-coverage rhesus red blood cell proteome: a first comparison with the human and mouse red blood cell. Blood Transfus. 2010;8(suppl 3):s126-s139.
14. Pasini EM, Kirkegaard M, Salerno D, Mortensen P, Mann M, Thomas AW. Deep coverage mouse red blood cell proteome: a first comparison with the human red blood cell. Mol Cell Proteomics. 2008;7(7):1317-1330.
15. Yeh E, DeRisi JL. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol. 2011;9(8):e1001138.
16. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976;193(4254):673-675.
17. Ribaut C, Berry A, Chevalley S, et al. Concentration and purification by magnetic separation of the erythrocytic stages of all human Plasmodium species. Malar J. 2008;7:45.
18. Rivadeneira EM, Wasserman M, Espinal CT. Separation and concentration of schizonts of Plasmodium falciparum by Percoll gradients. J Protozool. 1983;30(2):367-370.
19. Li Q, Gerena L, Xie L, Zhang J, Kyle D, Milhous W. Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Cytometry A. 2007;71(5):297-307.
20. Abitbol M, Bernex F, Puy H, et al. A mouse model provides evidence that genetic background modulates anemia and liver injury in erythropoietic protoporphyria. Am J Physiol Gastrointest Liver Physiol. 2005;288(6):G1208-G1216.
21. Li FM, Lim CK, Peters TJ. An HPLC assay for rat liver ferrochelatase activity. Biomed Chromatogr. 1987;2(4):164-168.
22. Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol. 2001;54(7):500-507.
23. Benton CM, Lim CK, Moniz C, Jones DJ. Ultra high-performance liquid chromatography of porphyrins in clinical materials: column and mobile phase selection and optimisation. Biomed Chromatogr. 2012;26(6):714-719.
24. Hall N, Karras M, Raine JD, et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science. 2005;307(5706):82-86.
25. Nagaraj VA, Arumugam R, Chandra NR, Prasad D, Rangarajan PN, Padmanaban G. Localisation of Plasmodium falciparum uroporphyrinogen III decarboxylase of the heme-biosynthetic pathway in the apicoplast and characterisation of its catalytic properties. Int J Parasitol. 2009;39(5):559-568.
26. Janse CJ, Franke-Fayard B, Mair GR, et al. High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol. 2006;145(1):60-70.
27. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-937.
28. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet. 2002;30(1):27-28.
29. To-Figueras J, Ducamp S, Clayton J, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood. 2011;118(6):1443-1451.
30. Ducamp S, Schneider-Yin X, de Rooij F, et al. Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). Hum Mol Genet. 2013;22(7):1280-1288.
31. Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83(3):408-414.
32. Lyoumi S, Abitbol M, Andrieu V, et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood. 2007;109(2):811-818.
33. Shi Z, Ferreira GC. Modulation of inhibition of ferrochelatase by N-methylprotoporphyrin. Biochem J. 2006;399(1):21-28.
34. Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006;9(4):388-394.
35. Gouya L, Martin-Schmitt C, Robreau AM, et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet. 2006;78(1):2-14.
36. Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood. 2007;110(12):4108-4110.
37. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Orphanet J Rare Dis. 2009;4:19.
38. Surolia N, Padmanaban G. De novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem Biophys Res Commun. 1992;187(2):744-750.
39. Sato S, Wilson RJ. Proteobacteria-like ferrochelatase in the malaria parasite. Curr Genet. 2003;42(5):292-300.
40. Foote SJ. Can nature's defence against malaria be mimicked by the development of host-directed therapies? Pharmacogenomics J. 2004;4(3):141-142.
41. Prudêncio M, Mota MM. Targeting host factors to circumvent anti-malarial drug resistance. Curr Pharm Des. 2013;19(2):290-299.